The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data
Abstract
This paper has reviewed the documentation on the clinical efficacy of choline alphoscerate, a cholinergic precursor, considered as a centrally acting parasympathomimetic drug in dementia disorders and in acute cerebrovascular disease. Thirteen published clinical trials, examining in total 4054 patients, have evaluated the use of choline alphoscerate in various forms of dementia disorders of degenerative, vascular or combined origin, such as senile dementia of the Alzheimer's type (SDAT) or vascular dementia (VaD) and in acute cerebrovascular diseases, such as transitory ischemic attack (TIA) and stroke. Analysis has assessed the design of each study, in particular with respect to experimental design, number of cases, duration of treatment and tests used to evaluate drug clinical efficacy. Most of the ten studies performed in dementia disorders were controlled trials versus a reference drug or placebo. Overall, 1570 patients were assessed in these studies, 854 of which in controlled trials. As detected by validated and appropriate tests, such as Mini Mental State Evaluation (MMSE) in SDAT and Sandoz Clinical Assessment Geriatric (SCAG) in VaD, administration of choline alphoscerate significantly improved patient clinical condition. Clinical results obtained with choline alphoscerate were superior or equivalent to those observed in control groups under active treatment and superior to the results observed in placebo groups. Analysis stresses the clear internal consistency of clinical data gathered by different experimental situations on the drug effect, especially with regard to the cognitive symptoms (memory, attention) characterising the clinical picture of adult-onset dementia disorders. The therapeutic usefulness of choline alphoscerate in relieving cognitive symptoms of chronic cerebral deterioration differentiates this drug from cholinergic precursors used in the past, such as choline and lecithin. Three uncontrolled trials were performed with choline alphoscerate in acute cerebrovascular stroke and TIA, totalling 2484 patients. The results of these trials suggest that this drug might favour functional recovery of patients with cerebral stroke and should be confirmed in future investigations aimed at establish the efficacy of the drug in achieving functional recovery of patients with acute cerebrovascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Though A-GPC has been shown to improve cognitive function in with persons suffering from vascular dementia [8, 9] these studies have generally used much larger doses of A-GPC (1000-1200 mg daily).”
From Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance (2017) · cites this paper as [9]
In the citing paper
“Though A-GPC has been shown to improve cognitive function in with persons suffering from vascular dementia [8, 9] these studies have generally used much larger doses of A-GPC (1000-1200 mg daily).”
From Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance (2017) · cites this paper as [9]
In the citing paper
“A large review of clinical studies on dementia or cerebrovascular disorders suggest favorable results for improved cognitive fucntion with A-GPC compared to control or placebo [9].”
From Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance (2017) · cites this paper as [9]
In the citing paper
“When investigated in clinically compromised or healthy aged populations, A-GPC studies have indicated that A-GPC supplementation enhances memory and cognitive function and is an effective treatment for neurodegenerative disorders such as Alzheimer’s disease and dementia [1,9].”
From Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men (2024) · cites this paper as [9]
In the citing paper
“When investigated in clinically compromised or healthy aged populations, A-GPC studies have indicated that A-GPC supplementation enhances memory and cognitive function and is an effective treatment for neurodegenerative disorders such as Alzheimer’s disease and dementia [1,9].”
From Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men (2024) · cites this paper as [9]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“To obtain the most objective and homogeneous overall evaluation of the efficacy of choline alphoscerate in studies on dementia disorders of degenerative origin, the results of Mini Mental State Evaluation (MMSE) (Folstein et al., 1975) in these trials were evaluated.”
Result(1976) · Medical Entomology and Zoology · Cited by 8,899
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · cited 3×
“A definite relationship is known to exist between the completeness of the cholinergic transmission and memory and cognitive abilities (Bartus et al., 1982).”
BackgroundInfluentialThe Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986 · cited 6×
“Moreover, each of the three tests used to evaluate the extent of the clinical improvement (MMSE, GDS, CGRS) gave comparable clinical results in the different experimental situations where they were used: +15/12% for MMSE, −20% for GDS, −19/21% for the CGRS scale; 3. in spite of limits deriving from the absence of cont…”
MethodInfluentialAlzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 1×
“…accompanied by decreased neocortical choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities, the major anabolic and catabolic enzymes for acetylcholine, respectively, was commonly reported in brains of demented subjects (Davies and Maloney, 1976; Whitehouse et al., 1981, 1982).”
BackgroundSELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 2×
“Significant loss of forebrain cholinergic neurons accompanied by decreased neocortical choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities, the major anabolic and catabolic enzymes for acetylcholine, respectively, was commonly reported in brains of demented subjects (Davies and Maloney, 1976; W…”
BackgroundPerry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042 · cited 1×
“Reduction in ChAT and AChE activity is related with the degree of dementia and neuropathological hallmarks of AD, confirming a close association between cholinergic biochemical abnormalities and the disease (Perry et al., 1978).”
BackgroundECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736 · cited 1×
“…accompanied by decreased neocortical choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities, the major anabolic and catabolic enzymes for acetylcholine, respectively, was commonly reported in brains of demented subjects (Davies and Maloney, 1976; Whitehouse et al., 1981, 1982).”
BackgroundAsher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,290
Research works printed but not linked: 11
- Ban, 1991, Choline alphoscerate in elderly patients with cognitive decline due to dementing illness, New Trends Clin. Neuropharmacol., 5, 1
- Canonico, 1990, Effetti neurochimici e comportamentali di α-GFC (colina alfoscerato), Basi. Raz. Ter., 20, 53
- Drago, 1990, Effetti comportamentali di α-GFC in modelli di invecchiamento cerebrale patologico, Basi. Raz. Ter., 20, 65
- Govoni, 1990, Effetti di αGFC sul comportamento di evitamento passivo del ratto e sui livelli di acetilcolina, Basi. Raz. Ter., 20, 55
- Paciaroni, 1993, Studio clinico di efficacia e tollerabilità di α-GFC (colina alfoscerato), controllato vs oxiracetam in pazienti affetti da declino cognitivo di grado lieve-moderato su base vascolare, Giorn. It. Ric. Clin. Ter., 14, 29
- Palleschi, 1992, Valutazione di efficacia e tollerabilità di α-GFC (colina alfoscerato) in pazienti affetti da declino cognitivo di grado lieve-moderato, Geriatria, 4, 61
- Reynolds J.E.F. (Eds.), 1996. Parasimpathomimetics. In: Martindale—The Extra Pharmacopoeia, thirty-first ed. Royal Pharmaceutical Society, London, pp. 1413–1428.
- Schettini, 1990, Effetto del trattamento in vivo con α-GFC (colina alfoscerato) sull'attività dei sistemi di trasduzione a livello cerebrale, Basi. Raz. Ter., 20, 23
- Schettini, 1993, Effetto della colina alfoscerato in pazienti anziani affetti da demenza degenerativa primaria, Basi. Raz. Ter., 23, 108
- Tomasina, 1991, Studio clinico dell'efficacia terapeutica e della tollerabilità della colina alfoscerato in 15 soggetti con compromissione delle funzioni cognitive successiva ad ischemia cerebrale focale acuta, Riv. Neuropsichiatria Sci. Affini., 37, 21
- Vezzetti, 1992, Valutazione clinica e strumentale dell‘effetto della colina alfoscerato sul decadimento cerebrale, Presse Med. It., 5, 141
Cited by
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
De Jesus Moreno Moreno, M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90023-3 · Cited by 188
Poly, C., Massaro, J. M., Seshadri, S., Wolf, P. A., Cho, E., Krall, E., Jacques, P. F., & Au, R. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.008938 · Cited by 159
“However, only temporary improvement has been found with these treatments (20, 25, 26).”
BackgroundAmenta, F., Parnetti, L., Gallai, V., & Wallin, A. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00310-4 · Cited by 148
Self-citationCholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment
Wang, J., Zhang, H., & Tang, X.-C. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.82 · Cited by 134
Metadata
- Authors
- Parnetti, L., Amenta, F., & Gallai, V.
- Affiliations
- University of Perugia (IT)
- Università di Camerino (IT)
- Corresponding author
- Parnetti, Lucilla
- Venue
- Mechanisms of Ageing and Development
- Publisher
- Elsevier BV
- Published
- 2001-11
- Volume
- 122
- Issue
- 16
- Pages
- 2041-2055
- ISSN
- 0047-6374 (ISSN-L)
- OpenAlex
- W2145884031
- Cited by
- 132
- References
- 44
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 16 · 2023: 8 · 2022: 15 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 2 · 2017: 7 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 4 · 2012: 7
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Mechanisms of Ageing and Development (publishedVersion)
- PubMed (publishedVersion)
- Unicam Scientific Publications (University of Camerino) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- choline alphoscerate, cognitive decline, dementia, Alzheimer's disease, vascular dementia, stroke, transient ischemic attack, acute cerebrovascular disease, clinical efficacy, functional recovery, attention and memory
- MeSH terms
- Cerebrovascular Disorders, Clinical Trials as Topic, Cognition Disorders, Glycerylphosphorylcholine, Humans, Parasympathomimetics, Periodicals as Topic, Statistics as Topic, Dementia, Vascular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. https://app.cochat.ai/papers/10.1016/s0047-6374(01)00312-8
- The paper
- Parnetti, L., Amenta, F., & Gallai, V. (2001). Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechanisms of Ageing and Development. https://doi.org/10.1016/s0047-6374(01)00312-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.